[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-24-data-sources-contextual-intelligence":3},["null","category",4,"content",5,"date",6,"description",7,"faq",8,"ogTitle",9,"readTime",10,"slug",11,"tags",12,"title",9],"Technology","\u003Ch2 class=\"text-3xl font-bold mb-6\">Data Source Architecture\u003C\u002Fh2>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 mb-6 leading-relaxed\">\n Contextual Intelligence ingests data from 24 distinct sources organized into five\n domains: regulatory authorities, patent offices, clinical trial registries, grants and\n funding databases, and market intelligence feeds. Each source is monitored on its own\n crawl schedule, from daily for high-volume regulatory sources to weekly for patent\n databases and grant repositories.\n \u003C\u002Fp>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 mb-6 leading-relaxed\">\n The platform processes over 18,000 signals per day across all sources, with an average\n detection latency of under 12 hours from source publication to signal availability.\n Our entity resolution engine cross-references company names, device identifiers,\n personnel, and grant recipients across sources to build unified organizational\n profiles from fragmented data.\n \u003C\u002Fp>\n\n \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">Regulatory Data Sources\u003C\u002Fh2>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 mb-6 leading-relaxed\">\n Regulatory data forms the backbone of our signal detection platform. We monitor 10\n regulatory authorities across North America, Europe, Asia-Pacific, and Latin America,\n covering the world's largest and most influential medical device markets.\n \u003C\u002Fp>\n\n \u003Cdiv class=\"grid md:grid-cols-2 gap-6 my-8\">\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">FDA (USA)\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm mb-3\">\n The US Food and Drug Administration is the world's most influential medical device\n regulator. We monitor FDA 510(k) clearances, PMA approvals, De Novo\n classifications, recall announcements, and establishment registration updates.\n Update frequency: daily. Average signal volume: 200+ per week.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">EUDAMED (European Union)\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm mb-3\">\n The European Database on Medical Devices is the central repository for EU MDR and\n IVDR compliance data. We monitor NB certificate issuances, UDI device\n registrations, vigilance data, and market surveillance notices. Update frequency:\n daily. Average signal volume: 150+ per week.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">ANVISA (Brazil)\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm mb-3\">\n Brazil's national health surveillance agency manages the largest medical device\n market in Latin America. We monitor device registration approvals, GMP\n certifications, and regulatory updates. Update frequency: daily. Average signal\n volume: 80+ per week.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">NMPA (China)\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm mb-3\">\n China's National Medical Products Administration oversees the world's\n second-largest medical device market. We monitor device registration certificates,\n change notifications, and import license updates. Update frequency: daily. Average\n signal volume: 100+ per week.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">PMDA (Japan)\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm mb-3\">\n The Pharmaceuticals and Medical Devices Agency is Japan's medical device\n regulatory body. We monitor Shonin marketing approval certificates, classification\n decisions, and safety updates. Update frequency: daily. Average signal volume: 60+\n per week.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">CDSCO (India)\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm mb-3\">\n India's Central Drugs Standard Control Organization regulates devices in one of\n the fastest-growing healthcare markets. We monitor import licenses, device\n registrations, and regulatory notifications. Update frequency: weekly. Average\n signal volume: 40+ per week.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">MFDS (South Korea)\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm mb-3\">\n South Korea's Ministry of Food and Drug Safety regulates medical devices in a\n sophisticated and rapidly aging market. We monitor device approvals, clinical\n trial authorizations, and GMP certifications. Update frequency: weekly. Average\n signal volume: 50+ per week.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">TGA (Australia)\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm mb-3\">\n The Therapeutic Goods Administration maintains the Australian Register of\n Therapeutic Goods (ARTG). We monitor new ARTG entries, certificate changes, and\n conformity assessment updates. Update frequency: daily. Average signal volume: 30+\n per week.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">Health Canada\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm mb-3\">\n Health Canada's Medical Devices Directorate licenses all medical devices sold in\n Canada. We monitor Medical Device License (MDL) issuances, MDEL registrations, and\n safety alerts. Update frequency: daily. Average signal volume: 40+ per week.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">WHO Prequalification\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm mb-3\">\n The World Health Organization's Prequalification Program evaluates medical devices\n and IVDs for global health procurement. We monitor PQ listings, inspection\n outcomes, and performance reports. Update frequency: weekly. Average signal\n volume: 10+ per week.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003C\u002Fdiv>\n\n \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">Patent Data Sources\u003C\u002Fh2>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 mb-6 leading-relaxed\">\n Patent data provides early visibility into R&D activity before regulatory submissions\n appear. Our platform monitors six major patent offices, covering the vast majority of\n global medical device and IVD patent filings.\n \u003C\u002Fp>\n\n \u003Cdiv class=\"grid md:grid-cols-3 gap-6 my-8\">\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-2\">USPTO\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n United States Patent and Trademark Office. Coverage: granted patents and published\n applications. Update frequency: weekly.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-2\">EPO\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n European Patent Office. Coverage: European patent grants and applications. Update\n frequency: weekly.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-2\">WIPO\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n World Intellectual Property Organization. Coverage: PCT international\n applications. Update frequency: weekly.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-2\">CNIPA\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n China National Intellectual Property Administration. Coverage: Chinese patent\n filings. Update frequency: weekly.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-2\">KIPO\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n Korean Intellectual Property Office. Coverage: South Korean patent filings. Update\n frequency: weekly.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-2\">JPO\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n Japan Patent Office. Coverage: Japanese patent filings. Update frequency: weekly.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003C\u002Fdiv>\n\n \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">Clinical Trial Data Sources\u003C\u002Fh2>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 mb-6 leading-relaxed\">\n Clinical trial activity is a leading indicator of product development progress and\n eventual regulatory submission. We monitor the two most comprehensive clinical trial\n registries globally.\n \u003C\u002Fp>\n\n \u003Cdiv class=\"grid md:grid-cols-2 gap-6 my-8\">\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">ClinicalTrials.gov\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n The US National Library of Medicine's clinical trials registry is the world's\n largest, with over 450,000 registered studies from 220+ countries. We monitor new\n trial registrations, status changes, and results submissions for medical device\n and IVD studies. Update frequency: daily. Average signal volume: 200+ per week.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">EU CTIS\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n The EU Clinical Trials Information System is the single entry point for clinical\n trial authorization under the EU Clinical Trial Regulation. We monitor trial\n applications, authorizations, and results for device and IVD studies. Update\n frequency: daily. Average signal volume: 80+ per week.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003C\u002Fdiv>\n\n \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">Grants and Funding Data Sources\u003C\u002Fh2>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 mb-6 leading-relaxed\">\n Grant and funding signals reveal where R&D investment is flowing before products reach\n the market. Government grants validate technology readiness, while private funding\n signals strategic direction and growth trajectory. These sources bridge the gap\n between early-stage research and commercial regulatory activity.\n \u003C\u002Fp>\n\n \u003Cdiv class=\"grid md:grid-cols-2 gap-6 my-8\">\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">Grants.gov\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n The US federal grants portal. We monitor SBIR\u002FSTTR awards and NIH grant funding\n relevant to medical device and diagnostic development. Grant recipients represent\n validated technology with non-dilutive funding. Update frequency: weekly.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">NIH RePORTER\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n The NIH Research Portfolio Online Reporting Tools database provides detailed\n information on NIH-funded research projects. We monitor awarded grants, research\n progress reports, and funding trends across institutes and centers. This source\n offers a broader view of federal research investment beyond the SBIR\u002FSTTR programs\n tracked in Grants.gov. Update frequency: weekly.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003C\u002Fdiv>\n\n \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">Market Intelligence Data Sources\u003C\u002Fh2>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 mb-6 leading-relaxed\">\n Market intelligence signals provide context on company financial health, competitive\n positioning, and strategic direction. These sources complement regulatory, clinical,\n and grant data to build a complete picture of every organization in our platform.\n \u003C\u002Fp>\n\n \u003Cdiv class=\"grid md:grid-cols-2 gap-6 my-8\">\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">Crunchbase\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n Leading platform for company funding data, including venture capital rounds,\n acquisitions, and IPOs in the MedTech and health technology sectors. Update\n frequency: daily.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">PitchBook\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n Comprehensive private market database covering venture capital, private equity,\n M&A transactions, and IPO activity in healthcare and life sciences. PitchBook\n provides deeper coverage of later-stage private company activity and detailed\n financial metrics. Update frequency: daily.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">SEC EDGAR\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n The SEC's Electronic Data Gathering, Analysis, and Retrieval system provides\n public company disclosures including 10-K annual reports, 8-K current reports, and\n S-1 registration statements. Update frequency: daily.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003Cdiv class=\"card bg-slate-50 p-6\">\n \u003Ch3 class=\"text-xl font-bold mb-3\">PubMed\u003C\u002Fh3>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 text-sm\">\n The National Library of Medicine's database of biomedical literature. We monitor\n publications relevant to medical devices and IVDs, including clinical studies,\n systematic reviews, and health technology assessments. Update frequency: weekly.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n \u003C\u002Fdiv>\n\n \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">Data Processing and Entity Resolution\u003C\u002Fh2>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 mb-6 leading-relaxed\">\n Raw data from global public sources is useless without intelligent processing. Our data pipeline\n performs several critical transformations: normalization of data formats from each\n source, de-duplication of records across sources (e.g., the same company appearing in\n FDA, ClinicalTrials.gov, and Crunchbase), entity resolution linking company names\n across languages and variations, and enrichment layering that combines regulatory,\n clinical, patent, grant, and market data into unified organizational profiles.\n \u003C\u002Fp>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 mb-6 leading-relaxed\">\n The entity resolution engine is particularly critical. A company called\n \"BioDiagnostics Inc.\" in FDA records may appear as \"Bio-Diagnostics, Inc.\" in\n ClinicalTrials.gov and \"BioDiagnostics\" on Crunchbase. Our resolution algorithms use\n fuzzy matching, address verification, and relationship graph analysis to unify these\n references into a single company entity.\n \u003C\u002Fp>\n\n \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">Coverage Frequency and Data Freshness\u003C\u002Fh2>\n \u003Cp class=\"text-slate-600 dark:text-slate-300 mb-6 leading-relaxed\">\n Data freshness is critical for signal intelligence. Our sources are crawled on\n schedules tailored to their publication patterns:\n \u003C\u002Fp>\n\n \u003Cdiv class=\"card bg-slate-50 p-6 my-8\">\n \u003Ch3 class=\"text-xl font-bold mb-4\">Crawl Schedule by Source Category\u003C\u002Fh3>\n \u003Cul class=\"space-y-2 text-slate-600 dark:text-slate-300\">\n \u003Cli>\n \u003Cstrong>Daily (13 sources):\u003C\u002Fstrong> FDA, EUDAMED, ANVISA, NMPA, PMDA, TGA, Health\n Canada, ClinicalTrials.gov, EU CTIS, SEC EDGAR, Crunchbase, PitchBook, Grants.gov\n \u003C\u002Fli>\n \u003Cli>\n \u003Cstrong>Weekly (11 sources):\u003C\u002Fstrong> CDSCO, MFDS, WHO PQ, USPTO, EPO, WIPO,\n CNIPA, KIPO, JPO, PubMed, NIH RePORTER\n \u003C\u002Fli>\n \u003C\u002Ful>\n \u003Cp class=\"text-xs text-slate-500 dark:text-slate-400 mt-3\">\n Schedules are subject to change based on source API availability and data volume.\n \u003C\u002Fp>\n \u003C\u002Fdiv>\n\n \u003Cp class=\"text-slate-600 dark:text-slate-300 mb-6 leading-relaxed\">\n The result is a continuously updated intelligence feed that detects signals within\n hours of publication, not days or weeks. For organizations monitoring competitive\n activity, partnership opportunities, or market trends, this speed differential\n translates directly into first-mover advantage.\n \u003C\u002Fp>\n\n \u003Cp class=\"text-slate-600 dark:text-slate-300 mb-8 leading-relaxed\">\n Each data source undergoes quarterly quality reviews to ensure coverage completeness,\n data accuracy, and detection latency meet our platform standards. When sources change\n their data formats or availability, our engineering team prioritizes rapid adaptation\n to maintain uninterrupted signal coverage.\n \u003C\u002Fp>","2026-01-01","Explore the 24 global regulatory, clinical, patent, grant, and market databases that power the Contextual Intelligence platform. FDA, EUDAMED, ANVISA, NMPA, PitchBook, and more.",null,"The 24 Data Sources Behind Contextual Intelligence",6,"24-data-sources-contextual-intelligence",[13],"technology"]